Fig. 2: pCR rates according to baseline PD-L1 CPS. | Nature Communications

Fig. 2: pCR rates according to baseline PD-L1 CPS.

From: Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

Fig. 2

A pCR rate according to PD-L1 CPS, using CPS cut-off of <1 (negative) vs >/=1 (positive). B pCR rate according to PD-L1 CPS, using CPS cut-off of <10 (negative) vs >/=10 (positive). In both panels, results are shown for the overall population (black column, n = 26 patients evaluable for PD-L1 CPS on baseline tissue) and for patients who did not (red column) versus who did (green column) receive neoadjuvant AC. AC was administered to patients with incomplete clinical response to neoadjuvant nab-paclitaxel plus pembrolizumab per physician discretion. Only the 26 patients evaluable for baseline PD-L1 CPS are shown in both panels. AC Adriamycin + cyclophosphamide, PD-L1 Programmed death-ligand 1, CPS Combined Positive Score.

Back to article page